Hims & Hers Health, Inc. HIMS
We take great care to ensure that the data presented and summarized in this overview for Hims & Hers Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HIMS
View all-
Vanguard Group Inc Valley Forge, PA19.5MShares$722 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA18.8MShares$695 Million0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY17.8MShares$658 Million0.07% of portfolio
-
Black Rock Inc. New York, NY14.6MShares$539 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA10.7MShares$397 Million2.64% of portfolio
-
New View Hms Spv Partners, LLC Burlingame, CA9.66MShares$357 Million100.0% of portfolio
-
Goldman Sachs Group Inc New York, NY9.22MShares$341 Million0.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny9.1MShares$336 Million0.73% of portfolio
-
Morgan Stanley New York, NY7.28MShares$269 Million0.03% of portfolio
-
State Street Corp Boston, MA7.17MShares$265 Million0.01% of portfolio
Latest Institutional Activity in HIMS
Top Purchases
Top Sells
About HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Insider Transactions at HIMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,070
-9.01%
|
$299,310
$33.79 P/Share
|
|
Jan 05
2026
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,986
+2.92%
|
$47,888
$8.27 P/Share
|
|
Dec 22
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,090
-19.66%
|
$808,150
$35.72 P/Share
|
|
Dec 17
2025
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
8,411
-79.82%
|
$302,796
$36.71 P/Share
|
|
Dec 17
2025
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,021
-5.57%
|
$360,756
$36.71 P/Share
|
|
Dec 17
2025
|
Deborah M. Autor Chief Policy Officer |
SELL
Open market or private sale
|
Direct |
7,054
-53.32%
|
$253,944
$36.71 P/Share
|
|
Dec 17
2025
|
Michael Chi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,750
-4.31%
|
$495,000
$36.71 P/Share
|
|
Dec 15
2025
|
Deborah M. Autor Chief Policy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,054
+34.78%
|
-
|
|
Dec 15
2025
|
Michael Chi Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,870
-11.11%
|
$1,435,320
$36.25 P/Share
|
|
Dec 15
2025
|
Michael Chi Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
72,106
+16.73%
|
-
|
|
Dec 15
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
58,010
-33.07%
|
$2,088,360
$36.25 P/Share
|
|
Dec 15
2025
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
105,201
+37.49%
|
-
|
|
Dec 15
2025
|
Irene Becklund PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,867
-45.7%
|
$319,212
$36.25 P/Share
|
|
Dec 15
2025
|
Irene Becklund PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,986
+48.1%
|
-
|
|
Dec 15
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90,660
-9.35%
|
$3,263,760
$36.25 P/Share
|
|
Dec 15
2025
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
164,369
+14.5%
|
-
|
|
Dec 15
2025
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,500
-3.49%
|
$234,000
$36.25 P/Share
|
|
Dec 15
2025
|
Patrick Harrison Carroll Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,521
+8.14%
|
-
|
|
Dec 15
2025
|
Soleil Boughton Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,817
-11.72%
|
$821,412
$36.25 P/Share
|
|
Dec 15
2025
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,421
+17.55%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 4.23M shares |
|---|---|
| Bona fide gift | 4.35M shares |
| Payment of exercise price or tax liability | 1.03M shares |
|---|---|
| Open market or private sale | 3.93M shares |
| Bona fide gift | 4.36M shares |
| Other acquisition or disposition | 260K shares |